Skip to main content

Qiagen Licenses DNA Amplification Technology from Genetrix

NEW YORK (GenomeWeb News) – Spanish biotechnology holding company Genetrix today announced it has licensed its Qualiphi polymerase product to Qiagen.

The global, exclusive deal was reached through Genetrix's X-Pol subsidiary.

Qualiphi is a DNA polymerase licensed from the Spanish National Research Council and studies suggest that it may improve the amplifications of whole genomes and large stretches of DNA, Genetrix said.

Financial and other terms of the deal were not disclosed.

Founded in 2011, Genetrix serves as an incubator for Spanish biotech companies established in academic settings. It has invested more than €36 million ($44.2 million) in nine companies with a focus on healthcare technologies, human therapies, and diagnostics.

X-Pol was created by Genetrix and Luis Blanco in 2008 and develops technologies for DNA amplification and sequencing. Genetrix owns 84 percent of the company.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.